MIR1261: A Drug Target / Disease Biomarker (G100302228)

MIR1261: A Drug Target / Disease Biomarker

MIR1261, also known as interleukin-1261, is a protein that is expressed in various tissues throughout the body. It is a cytokine that plays a critical role in the immune system, specifically in the regulation of T cell development and function. MIR1261 has been identified as a potential drug target and has been shown to have therapeutic potential in various diseases, including cancer, autoimmune disorders, and inflammatory diseases.

MIR1261 is a member of the interleukin-1 family, which includes several cytokines that play a crucial role in the immune system. These cytokines are responsible for regulating the recruitment and activation of immune cells, as well as modulating their functions to ensure an effective and appropriate response to an infection or inflammation. MIR1261 is specifically involved in the regulation of T cell development and function, which is a critical aspect of the immune system.

T cells are a type of immune cell that play a crucial role in protecting the body against infection and disease. They are responsible for recognizing and responding to foreign substances in the body, including viruses, bacteria, and other pathogens. T cells are also involved in the development and regulation of other immune cells, including B cells and natural killer cells. MIR1261 is involved in the regulation of T cell development and function by promoting the proliferation and differentiation of T cells, as well as by regulating their interactions with other immune cells.

MIR1261 has been shown to have a wide range of therapeutic potential in various diseases, including cancer, autoimmune disorders, and inflammatory diseases. For example, studies have shown that MIR1261 can be used to treat various forms of cancer, including breast, lung, and ovarian cancer. In these studies, MIR1261 has been shown to promote the growth and survival of cancer cells, as well as to inhibit the growth of healthy tissue.

In addition to its potential as a cancer drug, MIR1261 has also been shown to have potential in treating autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis. These disorders are characterized by an overactive immune system that attacks the body's own tissues, leading to inflammation and pain. MIR1261 has been shown to regulate the activity of immune cells and to reduce the production of antibodies that contribute to the development and progression of these disorders.

MIR1261 has also been shown to have potential as an anti-inflammatory drug. Chronic inflammation is associated with a number of diseases, including heart disease, diabetes, and cancer. MIR1261 has been shown to reduce the production of pro-inflammatory cytokines, such as TNF-alpha, IL-1, and IL-6, which are involved in the regulation of inflammation. This has led to potential therapeutic applications in reducing the risk of chronic inflammation and the development of inflammatory diseases.

In conclusion, MIR1261 is a protein that has been identified as a potential drug target and has been shown to have therapeutic potential in various diseases, including cancer, autoimmune disorders, and inflammatory diseases. Further research is needed to fully understand the mechanisms of MIR1261 and its potential as a therapeutic agent.

Protein Name: MicroRNA 1261

The "MIR1261 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR1261 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR1262 | MIR1263 | MIR1264 | MIR1265 | MIR1266 | MIR1267 | MIR1268A | MIR1268B | MIR1269A | MIR1269B | MIR127 | MIR1270 | MIR1271 | MIR1272 | MIR1273A | MIR1273C | MIR1273H | MIR1275 | MIR1276 | MIR1277 | MIR1278 | MIR1279 | MIR128-1 | MIR128-2 | MIR1280 | MIR1281 | MIR1282 | MIR1283-1 | MIR1283-2 | MIR1284 | MIR1285-1 | MIR1285-2 | MIR1286 | MIR1287 | MIR1288 | MIR1289-1 | MIR1289-2 | MIR129-1 | MIR129-2 | MIR1290 | MIR1291 | MIR1292 | MIR1293 | MIR1294 | MIR1295A | MIR1295B | MIR1296 | MIR1297 | MIR1298 | MIR1299 | MIR1301 | MIR1302-1 | MIR1302-10 | MIR1302-11 | MIR1302-2 | MIR1302-3 | MIR1302-4 | MIR1302-5 | MIR1302-6 | MIR1302-7 | MIR1302-8 | MIR1302-9 | MIR1303 | MIR1304 | MIR1305 | MIR1306 | MIR1307 | MIR130A | MIR130B | MIR132 | MIR1321 | MIR1322 | MIR1323 | MIR1324 | MIR133A1 | MIR133A1HG | MIR133A2 | MIR133B | MIR134 | MIR1343 | MIR135A1 | MIR135A2 | MIR135B | MIR136 | MIR137 | MIR137HG | MIR138-1 | MIR138-2 | MIR139 | MIR140 | MIR141 | MIR142 | MIR143 | MIR144 | MIR145 | MIR1468 | MIR1469 | MIR146A | MIR146B | MIR1470